从TRPV1、PAR-2表达探讨理气通便合剂治疗便秘型肠易激综合征研究

Study on Mechanism of Liqi Tongbian Decoction Treating IBS-C from Expressions of TRPV1 and PAR-2

目的:通过观察便秘型肠易激综合征(IBS-C)治疗前、后结肠黏膜TRPV1、PAR-2蛋白及其mRNA表达,探讨理气通便合剂干预IBS-C的可能机制。方法:30例符合诊断标准、纳入标准的IBS-C患者,予以理气通便合剂干预4周,采用荧光定量PCR、Western-blot技术检测治疗前后结肠TRPV1、PAR-2蛋白及其mRNA变化。结果:治疗前,IBS-C患者腹痛、腹部不适明显,伴见粪质坚硬,排便时间延长;予理气通便合剂干预14 d、28 d后,患者腹痛、腹部不适缓解,粪质变软,排便时间缩短,与治疗前比较,有统计学意义(P<0.05)。治疗前,IBS-C患者结肠黏膜TRPV1、PAR-2呈高表达变化;治疗后,TRPV1、PAR-2表达下降,有统计学意义(P<0.05)。结论:理气通便合剂可能通过降低TRPV1、PAR-2表达,发挥缩短排便时间,改善大便性状的效用。

Objective： The intervention effect of Liqi Tongbian Decoction treating with IBS - C was discussed by ob- serving the clinical manifestation and the expression of TRPV1 and PAR - 2 of IBS - C before and after treatment. Methods： Thirty IBS- C patients met the diagnosis criteria and including criteria were administrated with Liqi Tongbian Decoction for four weeks. The expressions of TRPV1 and PAR-2 were assayed by Reat- time PCR and Western- blot respectively. Results： Before treatment, the IBS -C patients were characterized by abdominal pain and abdominal disten- sion as well as dry feces and elongation of defecation time. After treated with Liqi Tongbian Decoction, the above clinical symptoms we mentioned were improved（ P 〈 0.05）. Before treatment, the expressions of TRPV1 and PAR- 2 in colon mucosa were in the increment. However, expressions of TRPV1 and PAR - 2 in colon mucosa were on the decline after treatment（ P 〈0.05 ）. Conclusions： Liqi Tongbian Decoction exerts a distinct effect on regulating abdominal pain and abdominal distension as well as shortening defecation time and improving stool by mediating the expressions of TRPV1 and PAR - 2.